Proliferation Soluble CD83 Proteins That Inhibit T Cell Alternative

Total Page:16

File Type:pdf, Size:1020Kb

Proliferation Soluble CD83 Proteins That Inhibit T Cell Alternative Alternative Splicing Generates Putative Soluble CD83 Proteins That Inhibit T Cell Proliferation This information is current as Diana Dudziak, Falk Nimmerjahn, Georg W. Bornkamm and of September 23, 2021. Gerhard Laux J Immunol 2005; 174:6672-6676; ; doi: 10.4049/jimmunol.174.11.6672 http://www.jimmunol.org/content/174/11/6672 Downloaded from References This article cites 36 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/174/11/6672.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 23, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Alternative Splicing Generates Putative Soluble CD83 Proteins That Inhibit T Cell Proliferation1 Diana Dudziak,2* Falk Nimmerjahn,3† Georg W. Bornkamm,* and Gerhard Laux* CD83 is expressed on mature dendritic cells and activated lymphocytes and has been implicated to play an important role during T cell development in the thymus. In contrast, not much is known about the function of CD83 in the periphery. Soluble forms of CD83 have been detected in the serum, but neither the function nor the mechanism of how these soluble forms of CD83 are generated are fully understood. In this study, we report the identification of four different transcripts of CD83 in unstimulated PBMCs. Sequence analysis demonstrated that the longest form codes for transmembrane CD83 (CD83-TM), whereas the smaller transcripts are splice variants of full-length CD83, coding for putative soluble CD83 proteins. Stimulation of PBMCs with PHA, TNF-␣, or LPS leads to the up-regulation of the full-length CD83 transcript and to a strong down-regulation of two of the three smaller transcripts. The smallest CD83 splice product can be translated efficiently into protein, and recombinant soluble CD83 shows a strong inhibitory effect on T cell proliferation in MLRs. Our results suggest that the constitutive production of soluble Downloaded from forms of CD83 under steady-state conditions may have an important function in regulating immune homeostasis. The Journal of Immunology, 2005, 174: 6672–6676. he surface glycoprotein CD83 has a molecular mass of are rejected after injection into C3H/HeN mice, whereas wild-type 40–45 kDa and belongs to the Ig superfamily (1, 2). It melanoma cells showed tumor growth (16, 17). consists of an extracellular V-type Ig-like domain at the N The addition of a human CD83-Ig fusion protein or a human http://www.jimmunol.org/ T 4 terminus, one transmembrane (TM) domain, and a short intracel- soluble CD83 protein lacking the TM and cytosolic domain lular cytoplasmic domain of 39 aa (2). CD83 is described as a cell strongly inhibited MLR or DC-mediated allogeneic T cell prolif- surface marker of mature dendritic cells including Langerhans eration, demonstrating that soluble CD83 could have an inhibitory cells in the skin and interdigitating reticulum cells in the T cell function (18). Moreover, soluble CD83 was able to prevent exper- zones of the lymph nodes (2–5). In immature monocyte-derived imental autoimmune encephalomyelitis (EAE) in C57BL/6 mice dendritic cells (MoDCs), CD83 is up-regulated after stimulation (19). Latest studies suggest that soluble CD83 is present in the with LPS, TNF-␣, or CD40L (6–8). Addition of high doses of serum of healthy donors (20–22) and it was proposed that the IL-4, GM-CSF, and TNF-␣ induces the expression of CD83 on mechanism for the generation of soluble CD83 is shedding of cell by guest on September 23, 2021 monocytes, granulocyte-precursor cells, and myelocytes (9, 10). It surface-associated CD83. However, soluble forms of cell surface was also shown that CD83 is expressed on polymorphonuclear proteins can also result from alternative splicing as reported for neutrophils (11) and on murine thymus epithelial cells (12). Fur- several members of the Ig superfamily, e.g., CD80 (B7-1), CD86 thermore, CD83 is expressed on Hodgkin cells (13) and EBV- (B7-2), CTLA-4, or CD28 (23–28). transformed lymphoblastoid cell lines (2, 14). In this study, we report that alternative splicing generates soluble The function of CD83 remains largely unknown. CD83 knock- forms of CD83. Stimulation of freshly isolated PBMCs with PHA, out mice showed a block in the development of CD4ϩ single- LPS, or TNF-␣/IL-1␤ up-regulates transcripts encoding TM CD83 positive T cells (12). CD83 expression on mature dendritic cells and down-regulates transcripts coding for alternatively spliced prod- and activated lymphocytes (1, 2, 10, 15) suggests that CD83 might ucts of CD83. These putative soluble forms of CD83 proteins are be involved in activating immune effector cells. Along these lines, characterized by a partial deletion of the extracellular and the TM melanoma cells that were engineered to express cell surface CD83 domain. Soluble CD83 displayed inhibitory effects in MLRs and, therefore, might have important immunoregulatory functions in vivo. *Institute of Clinical Molecular Biology and Tumor Genetics, GSF National Research Materials and Methods Center (GSF) for Environment and Health and †Clinical Cooperation Group of Pe- Isolation of human PBMCs and DCs diatric Oncology, GSF and Children’s Hospital of the Technical University, Munich, Germany Human PBMCs were isolated by centrifugation on Ficoll-Paque (Amer- sham Biosciences). Isolated PBMCs were cultured in complete medium Received for publication September 15, 2004. Accepted for publication March (RPMI 1640 medium; Invitrogen Life Technologies) supplemented with 15, 2005. 10% FCS (Dynacyte), 100 U/ml penicillin, 100 ␮g/ml streptomycin, 1 mM The costs of publication of this article were defrayed in part by the payment of page sodium-pyruvate, 2 mM L-glutamine (all from Invitrogen Life Technolo- charges. This article must therefore be hereby marked advertisement in accordance gies) and were left either unstimulated or stimulated with PHA (1 ␮g/ml), with 18 U.S.C. Section 1734 solely to indicate this fact. LPS (1 ␮g/ml), or a mix of TNF-␣ (2.5 ng/ml; Sigma-Aldrich), IL-1␤ (1 1 This work was supported by a grant from Deutsche Forschungsgemeinschaft ng/ml; Sigma-Aldrich), and PGE2 (1 ng/ml; Sigma-Aldrich) for the indi- (SFB455; to F.N.). G.W.B. was supported by Fonds der Chemischen Industrie. cated time. Human DCs were generated as described (4) and matured with 2 ␣ ␤ Address correspondence and reprint requests to Dr. Diana Dudziak at the current LPS (100 ng/ml) or TNF- /IL-1 /PGE2. address: Laboratory of Molecular Immunology, The Rockefeller University, Box 220, 1230 York Avenue, New York, NY 10021. E-mail address: [email protected] Cloning and sequencing of the CD83 mRNA splice products 3 Current address: Laboratory of Molecular Genetics and Immunology, The Rock- Total RNA of PBMCs was extracted using the RNeasy Midi kit (Qiagen). efeller University, 1230 York Avenue, New York, NY 10021 RNA from human tissues was kindly provided by J. Mautner (Clinical 4 Abbreviations used in this paper: TM, transmembrane; MoDC, monocyte-derived Cooperation Group of Pediatric Oncology, GSF, Munich, Germany). Sin- dendritic cell; ORF, open reading frame. gle-stranded cDNA was synthesized from 5 ␮g of total RNA by reverse Copyright © 2005 by The American Association of Immunologists, Inc. 0022-1767/05/$02.00 The Journal of Immunology 6673 transcription using Superscript reverse transcriptase (Invitrogen Life Tech- Results nologies) and an oligo-dT primer (Amersham Biosciences) at 42°C. CD83 Identification of alternatively spliced variants of the CD83 mRNA cDNA was amplified with primers designed to amplify the entire coding sequence of CD83 (5Ј-GCGGGGGAATTCCTCGAGATGTCGCGCGG Recently, it was shown that soluble CD83 variants are present in CCTCCAGCTTC-3Ј and 5Ј-CCCCGGGCGGCCGCTCATACCAGTTCT the serum of healthy individuals and that they are enriched in leu- GTCTTGTGAGGAGTC-3Ј; Metabion). The PCR was performed using PFU DNA Polymerase (Promega) as follows: 94°C for 4 min, than 35 kemia patients (20–22). To examine whether soluble CD83 forms cycles of 94°C for 1 min, 57°C for 1 min, and 72°C for 2 min, followed by are generated by alternative splicing, we isolated total RNA from a final extension step at 72°C for 10 min (PerkinElmer). The amplified PBMCs that were either left untreated or treated for 4 or 16 h with fragments were separated on a 2% agarose gel and visualized by PHA (Fig. 1A) or for 16 h with LPS or TNF-␣/IL-1␤, respectively ethidium bromide. After excision from the gel, resulting products were (Fig. 1B). Stimulation of PBMCs with PHA was followed by cloned into the pcDNA3.1 vector. Cloned cDNAs were verified by se- quencing (Sequiserve). RNA integrity and cDNA synthesis was proven FACS analysis with an anti-human CD83-PE-labeled Ab showing by amplifying GAPDH cDNA (5Ј-ACCACAGTCCATGCCATCAC-3Ј a strong induction of CD83 on the cell surface of PBMCs 4 h after and 5Ј-TCCACCACCCTGTTGCTGTA-3Ј). PHA addition (Fig. 1C). The amplification of the CD83 coding sequence by RT-PCR using primers flanking the ATG initiation Generation of His-tagged soluble CD83 codon and the translation termination codon revealed the consti- tutive expression of four transcripts by nonactivated PBMCs, with CD83 splice variants were tagged with a C-terminal histidine hexapep- tide.
Recommended publications
  • Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes
    Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes This information is current as Joe M. Horvatinovich, Elizabeth W. Grogan, Marcus Norris, of September 29, 2021. Alexander Steinkasserer, Henrique Lemos, Andrew L. Mellor, Irina Y. Tcherepanova, Charles A. Nicolette and Mark A. DeBenedette J Immunol 2017; 198:2286-2301; Prepublished online 13 February 2017; Downloaded from doi: 10.4049/jimmunol.1600802 http://www.jimmunol.org/content/198/6/2286 Supplementary http://www.jimmunol.org/content/suppl/2017/02/11/jimmunol.160080 http://www.jimmunol.org/ Material 2.DCSupplemental References This article cites 80 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/198/6/2286.full#ref-list-1 Why The JI? Submit online. by guest on September 29, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Cx3cr1 Mediates the Development of Monocyte-Derived Dendritic Cells During Hepatic Inflammation
    CX3CR1 MEDIATES THE DEVELOPMENT OF MONOCYTE-DERIVED DENDRITIC CELLS DURING HEPATIC INFLAMMATION. Supplementary material Supplementary Figure 1: Liver CD45+ myeloid cells were pre-gated for Ly6G negative cells for excluding granulocytes and HDCs subsequently analyzed among the cells that were CD11c+ and had high expression of MHCII. Supplementary Table 1 low/- high + Changes in gene expression between CX3CR1 and CX3CR1 CD11b myeloid hepatic dendritic cells (HDCs) from CCl4-treated mice high Genes up-regulated in CX3CR1 HDCs Gene Fold changes P value Full name App 4,01702 5,89E-05 amyloid beta (A4) precursor protein C1qa 9,75881 1,69E-22 complement component 1, q subcomponent, alpha polypeptide C1qb 9,19882 3,62E-20 complement component 1, q subcomponent, beta polypeptide Ccl12 2,51899 0,011769 chemokine (C-C motif) ligand 12 Ccl2 6,53486 6,37E-11 chemokine (C-C motif) ligand 2 Ccl3 4,99649 5,84E-07 chemokine (C-C motif) ligand 3 Ccl4 4,42552 9,62E-06 chemokine (C-C motif) ligand 4 Ccl6 3,9311 8,46E-05 chemokine (C-C motif) ligand 6 Ccl7 2,60184 0,009272 chemokine (C-C motif) ligand 7 Ccl9 4,17294 3,01E-05 chemokine (C-C motif) ligand 9 Ccr2 3,35195 0,000802 chemokine (C-C motif) receptor 2 Ccr5 3,23358 0,001222 chemokine (C-C motif) receptor 5 Cd14 6,13325 8,61E-10 CD14 antigen Cd36 2,94367 0,003243 CD36 antigen Cd44 4,89958 9,60E-07 CD44 antigen Cd81 6,49623 8,24E-11 CD81 antigen Cd9 3,06253 0,002195 CD9 antigen Cdkn1a 4,65279 3,27E-06 cyclin-dependent kinase inhibitor 1A (P21) Cebpb 6,6083 3,89E-11 CCAAT/enhancer binding protein (C/EBP),
    [Show full text]
  • (Siglec) Adhesion Receptor That Binds CD83
    CD83 Is a Sialic Acid-Binding Ig-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8+ T Cells This information is current as of September 25, 2021. Nathalie Scholler, Martha Hayden-Ledbetter, Karl-Erik Hellström, Ingegerd Hellström and Jeffrey A. Ledbetter J Immunol 2001; 166:3865-3872; ; doi: 10.4049/jimmunol.166.6.3865 http://www.jimmunol.org/content/166/6/3865 Downloaded from References This article cites 44 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/166/6/3865.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts Errata An erratum has been published regarding this article. Please see next page or: /content/182/3/1772.2.full.pdf The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. CD83 Is a Sialic Acid-Binding Ig-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8؉ T Cells1 Nathalie Scholler,2* Martha Hayden-Ledbetter,† Karl-Erik Hellstro¨m,* Ingegerd Hellstro¨m,* and Jeffrey A.
    [Show full text]
  • Expansions of Adaptive-Like NK Cells with a Tissue-Resident Phenotype in Human Lung and Blood
    Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood Demi Brownliea,1, Marlena Scharenberga,1, Jeff E. Moldb, Joanna Hårdb, Eliisa Kekäläinenc,d,e, Marcus Buggerta, Son Nguyenf,g, Jennifer N. Wilsona, Mamdoh Al-Amerih, Hans-Gustaf Ljunggrena, Nicole Marquardta,2,3, and Jakob Michaëlssona,2 aCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, 14152 Stockholm, Sweden; bDepartment of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden; cTranslational Immunology Research Program, University of Helsinki, 00014 Helsinki, Finland; dDepartment of Bacteriology and Immunology, University of Helsinki, 00014 Helsinki, Finland; eHelsinki University Central Hospital Laboratory, Division of Clinical Microbiology, Helsinki University Hospital, 00290 Helsinki, Finland; fDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; gInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; and hThoracic Surgery, Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, 171 76 Stockholm, Sweden Edited by Marco Colonna, Washington University in St. Louis School of Medicine, St. Louis, MO, and approved January 27, 2021 (received for review August 18, 2020) Human adaptive-like “memory” CD56dimCD16+ natural killer (NK) We and others recently identified a subset of tissue-resident − cells in peripheral blood from cytomegalovirus-seropositive indi- CD49a+CD56brightCD16 NK cells in the human lung (14, 15). viduals have been extensively investigated in recent years and are The human lung is a frequent site of infection with viruses such currently explored as a treatment strategy for hematological can- as influenza virus and HCMV, as well as a reservoir for latent cers.
    [Show full text]
  • The CD83 Reporter Mouse Elucidates the Activity of the CD83 Promoter in B, T, and Dendritic Cell Populations in Vivo
    The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo Matthias Lechmann*, Naomi Shuman, Andrew Wakeham, and Tak W. Mak* Campbell Family Institute for Breast Cancer Research and Ontario Cancer Institute, University of Toronto, Toronto, ON, Canada M5G 2C1 Contributed by Tak W. Mak, July 1, 2008 (sent for review December 11, 2007) CD83 is the major surface marker identifying mature dendritic cells (22). However, truncated splice forms of CD83 have yet to be (DCs). In this study, we report the generation of reporter mice detected in human serum. At least some sCD83 may be generated expressing EGFP under the control of the CD83 promoter. We have by proteolytic cleavage of mCD83 (20). used these mice to characterize CD83 expression by various im- Although the CD83 ligand remains a mystery, analyses of gene- mune system cell types both in vivo and ex vivo and under targeted CD83-deficient mice have revealed that thymic CD83 steady-state conditions and in response to stimulation with a expression is crucial for the maturation of CD4ϩCD8ϩ thymocytes Toll-like receptor (TLR) ligand. With those mice we could prove in into CD4ϩ T cells (13, 14). In addition, CD83 may regulate the vivo that the CD83 promoter is highly active in all DCs and B cells intercellular interactions between DCs and peripheral T and B cells in lymphoid organs. Interestingly, this promoter activity in B cells (12, 23–25). In vitro culture of either human or murine lymphocytes mainly depended on the stage of development, is up-regulated in in the presence of sCD83 inhibits their proliferation (26, 27).
    [Show full text]
  • Tocilizumab Contributes to the Inflammatory Status of Mature Dendritic Cells Through Interleukin-6 Receptor Subunits Modulation
    ORIGINAL RESEARCH published: 16 August 2017 doi: 10.3389/fimmu.2017.00926 Tocilizumab Contributes to the inflammatory status of Mature Dendritic Cells through Interleukin-6 Receptor Subunits Modulation Daniel Meley1, Audrey Héraud 1, Valerie Gouilleux-Gruart2,3, Fabrice Ivanes1,4 and Florence Velge-Roussel 1,5* 1 EA 4245 Cellules Dendritiques, Immuno-modulation et Greffes, Université François-Rabelais de Tours, UFR de Médecine, Tours, France, 2 CNRS UMR 7292; Université François-Rabelais de Tours, UFR de Médecine, Tours, France, 3 Department of Immunology, CHRU de Tours, Tours, France, 4 Service de Cardiologie, CHRU de Tours, Tours, France, 5 UFR des Sciences Pharmaceutiques, Tours, France Tocilizumab, a humanized anti-IL-6 receptor α (IL-6Rα) is widely used in the treatment of a panel of pathologies such as adult and juvenile rheumatoid arthritis (RA) and the Edited by: systemic form of juvenile idiopathic arthritis in children. Its indications are expected to José Mordoh, Fundación Instituto Leloir, be largely extended to other inflammatory diseases in close future. Dendritic cells (DCs) Argentina appear to be deeply involved in the immunopathology of these diseases, yet the effects Reviewed by: of tocilizumab on these cells were poorly studied. In this study, we explored the effect Daniel Olive, Institut national de la santé et de la of tocilizumab on the regulation of IL-6R subunits [gp130, soluble form of IL-6Rα (sIL- recherche médicale, France 6Rα), and mIL-6Rα] in human monocyte-derived DCs. Human DCs were derived from Gilles Chiocchia, CD14+ monocytes purified with beads with IL-4 and granulocyte macrophage colony- Institut national de la santé et de la recherche médicale, France stimulating factor.
    [Show full text]
  • CD83 Modulates B Cell Activation and Germinal Center Responses
    CD83 Modulates B Cell Activation and Germinal Center Responses Lena Krzyzak, Christine Seitz, Anne Urbat, Stefan Hutzler, Christian Ostalecki, Joachim Gläsner, Andreas Hiergeist, This information is current as André Gessner, Thomas H. Winkler, Alexander of September 26, 2021. Steinkasserer and Lars Nitschke J Immunol published online 16 March 2016 http://www.jimmunol.org/content/early/2016/03/16/jimmun ol.1502163 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/03/16/jimmunol.150216 Material 3.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published March 16, 2016, doi:10.4049/jimmunol.1502163 The Journal of Immunology CD83 Modulates B Cell Activation and Germinal Center Responses Lena Krzyzak,* Christine Seitz,* Anne Urbat,† Stefan Hutzler,† Christian Ostalecki,‡ Joachim Gla¨sner,x Andreas Hiergeist,x Andre´ Gessner,x Thomas H. Winkler,{ Alexander Steinkasserer,*,1 and Lars Nitschke†,1 CD83 is a maturation marker for dendritic cells.
    [Show full text]
  • Mouse CD Marker Chart Bdbiosciences.Com/Cdmarkers
    BD Mouse CD Marker Chart bdbiosciences.com/cdmarkers 23-12400-01 CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD1d CD1.1, CD1.2, Ly-38 Lipid, Glycolipid Ag + + + + + + + + CD104 Integrin b4 Laminin, Plectin + DNAX accessory molecule 1 (DNAM-1), Platelet and T cell CD226 activation antigen 1 (PTA-1), T lineage-specific activation antigen 1 CD112, CD155, LFA-1 + + + + + – + – – CD2 LFA-2, Ly-37, Ly37 CD48, CD58, CD59, CD15 + + + + + CD105 Endoglin TGF-b + + antigen (TLiSA1) Mucin 1 (MUC1, MUC-1), DF3 antigen, H23 antigen, PUM, PEM, CD227 CD54, CD169, Selectins; Grb2, β-Catenin, GSK-3β CD3g CD3g, CD3 g chain, T3g TCR complex + CD106 VCAM-1 VLA-4 + + EMA, Tumor-associated mucin, Episialin + + + + + + Melanotransferrin (MT, MTF1), p97 Melanoma antigen CD3d CD3d, CD3 d chain, T3d TCR complex + CD107a LAMP-1 Collagen, Laminin, Fibronectin + + + CD228 Iron, Plasminogen, pro-UPA (p97, MAP97), Mfi2, gp95 + + CD3e CD3e, CD3 e chain, CD3, T3e TCR complex + + CD107b LAMP-2, LGP-96, LAMP-B + + Lymphocyte antigen 9 (Ly9),
    [Show full text]
  • Human CD83-Targeted Chimeric Antigen Receptor T Cells Prevent and Treat Graft-Versus-Host Disease
    RESEARCH ARTICLE The Journal of Clinical Investigation Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease Bishwas Shrestha,1 Kelly Walton,2 Jordan Reff,1 Elizabeth M. Sagatys,3,4 Nhan Tu,4 Justin Boucher,4 Gongbo Li,4 Tayyebb Ghafoor,4 Martin Felices,2 Jeffrey S. Miller,2 Joseph Pidala,4,5 Bruce R. Blazar,6 Claudio Anasetti,4,5 Brian C. Betts,2 and Marco L. Davila1,4,5 1Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA. 2Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. 3Department of Hematopathology and Laboratory Medicine, Moffitt Cancer Center, Tampa, Florida, USA. 4Department of Oncologic Sciences, University of South Florida, Tampa, Florida, USA. 5Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. 6Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. Graft-versus-host disease (GVHD) remains an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). For decades, GVHD prophylaxis has included calcineurin inhibitors, despite their incomplete efficacy and impairment of graft-versus-leukemia (GVL). Distinct from pharmacologic immune suppression, we have developed what we believe is a novel, human CD83-targeted chimeric antigen receptor (CAR) T cell for GVHD prevention. CD83 is expressed on allo-activated conventional CD4+ T cells (Tconvs) and proinflammatory dendritic cells (DCs), which are both implicated in GVHD pathogenesis. Human CD83 CAR T cells eradicate pathogenic CD83+ target cells, substantially increase the ratio of regulatory T cells (Tregs) to allo-activated Tconvs, and provide durable prevention of xenogeneic GVHD.
    [Show full text]
  • Differential Effects of PD-L1 Versus PD-1 Blockade on Myeloid Inflammation in Human Cancer
    Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer Noffar Bar, … , Kavita M. Dhodapkar, Madhav Dhodapkar JCI Insight. 2020. https://doi.org/10.1172/jci.insight.129353. Clinical Medicine In-Press Preview Hematology Immunology Introduction: PD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigorate T cells in diverse tumor types. Data for biologic effects of checkpoint blockade in human premalignancy are limited. Methods: We analyzed the immunologic effects of PD-L1 blockade in a clinical trial of atezolizumab in patients with asymptomatic multiple myeloma (AMM), a precursor to clinical malignancy. Genomic signatures of PD-L1 blockade in purified monocytes and T cells in vivo were also compared to those following PD-1 blockade in lung cancer patients. Effects of PD-L1 blockade on monocyte-derived dendritic cells were analyzed to better understand its effects on myeloid antigen- presenting cells. Results: In contrast to anti-PD-1 therapy, anti-PD-L1 therapy led to a distinct inflammatory signature in CD14+ monocytes and increase in myeloid-derived cytokines (e.g. IL-18) in vivo. Treatment of AMM patients with atezolizumab led to rapid activation and expansion of circulating myeloid cells which persisted in the bone marrow. Blockade of PD-L1 on purified monocyte-derived dendritic cells (DCs) led to rapid inflammasome activation and synergized with CD40L-driven DC maturation, leading to greater antigen-specific T cell expansion. Conclusions: These data show that PD-L1 blockade leads to distinct systemic […] Find the latest version: https://jci.me/129353/pdf Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer Noffar Bar1*, Federica Costa2,3*, Rituparna Das2*, Alyssa Duffy2*, Mehmet Samur4, Samuel McCachren2, Scott N.
    [Show full text]
  • Human Small Cell Lung Carcinoma and Carcinoid Tumor Regulate Dendritic Cell Maturation and Function Nora S
    Human Small Cell Lung Carcinoma and Carcinoid Tumor Regulate Dendritic Cell Maturation and Function Nora S. Katsenelson, Galina V. Shurin, Svetlana N. Bykovskaia, Jeffrey Shogan, Michael R. Shurin Department of Pathology (NSK, GVS, MRS), University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; and Bone Marrow Transplantation Program (SNB, JS), Allegheny General Hospital, Pittsburgh, Pennsylvania KEY WORDS: Apoptosis, Bronchial carcinoid tumor, The induction of apoptosis in dendritic cells (DC) is Dendritic cell, Immunohistochemistry, Small-cell a key mechanism by which tumors escape immune lung carcinoma. recognition and elimination. In fact, a number of Mod Pathol 2001;14(1):40–45 studies have showed the correlation between the number of DC within the tumor and the clinical Immune responses to tumor antigens are the result prognosis, suggesting that increased infiltration of of reciprocal communication between antigen- tumor tissue by DC was associated with better pa- presenting cells, T cells, and B cells. The most po- tient survival and low incidence of metastatic dis- tent professional antigen-presenting cells are den- ease. We compared the number of DC and their dritic cells (DC), which are considered to be solely distribution pattern in human small-cell lung car- responsible for initiating primary immune re- cinoma and bronchial carcinoid tumor (CT) tissues. sponses, including antitumor immunity (1, 2). DC Immunohistochemical analysis revealed the pres- recognize and take up antigen, process it, and ence of cells expressing DC markers CD1a and CD83 present antigenic peptides to T cells in a major in small-cell lung carcinoma tissues and the com- histocompatibility complex (MHC)–restricted man- plete absence of these cells in CT samples.
    [Show full text]
  • Insulin-Like Growth Factor I Promotes Maturation and Inhibits Apoptosis of Immature Cord Blood Monocyte–Derived Dendritic Cells Through MEK and PI 3-Kinase Pathways
    0031-3998/03/5406-0919 PEDIATRIC RESEARCH Vol. 54, No. 6, 2003 Copyright © 2003 International Pediatric Research Foundation, Inc. Printed in U.S.A. Insulin-Like Growth Factor I Promotes Maturation and Inhibits Apoptosis of Immature Cord Blood Monocyte–Derived Dendritic Cells through MEK and PI 3-Kinase Pathways ENMEI LIU, HELEN K.W. LAW, AND YU-LUNG LAU Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China ABSTRACT IGF-I has profound effects on the immune system. We pre- DC maturation and apoptosis. On the contrary, neutralizing viously reported that IGF-I promoted cord blood (CB)-naïve TNF-␣ significantly increased the IGF-I–induced up-regulation T-cell maturation and now show that IGF-I promoted maturation of CD83 and CD40. We conclude that IGF-I has maturation and of CB monocyte–derived dendritic cells (DC) with up-regulation survival effects on CB DC. These effects are mediated through of CD83, CD86, CD40, and major histocompatibility complex both MEK and PI 3-kinase pathways but not through the IGF-I (MHC) class II molecules, and down-regulation of mannose induction of TNF-␣ production by the DC. (Pediatr Res 54: receptor. Furthermore, IGF-I inhibited apoptosis of CB DC and 919–925, 2003) increased the production of tumor necrosis factor ␣ (TNF-␣). These effects were blocked by specific mitogen-activated protein Abbreviations kinase kinase (MEK) inhibitor (PD98059) and phosphoinositol AV, annexin V 3-kinase inhibitor (LY294002). PD98059 partially inhibited the CB, cord blood IGF-I–induced up-regulation of MHC class II.
    [Show full text]